Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial
Listen to this summary
The authors aimed to evaluate the efficacy and safety of oral deucrictibant, a bradykinin B2 receptor antagonist, for on-demand treatment of hereditary angioedema attacks in a phase 3 clinical trial. The study found that deucrictibant significantly reduced the time to symptom relief compared to placebo, with a median onset of 1.28 hours versus more than 12 hours for placebo, and was generally well tolerated. These findings suggest that deucrictibant may fulfill a critical need for effective and convenient oral treatment options for this condition.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Lancet (London, England)
View all →Oct 11, 2026 · Lancet (London, England)
Strengthening health systems to prioritise, provide care, and prevent osteoarthritis: a roadmap for global health policy
Oct 10, 2026 · Lancet (London, England)
Addressing threats to future global health-what is the right timeframe?
Oct 8, 2026 · Lancet (London, England)
Conversational diagnostic artificial intelligence in ambulatory primary care: a prospective feasibility study
Oct 7, 2026 · Lancet (London, England)
Migraine
Oct 4, 2026 · Lancet (London, England)
Governing the digital determinants of health for children and young people: a global public health imperative
Oct 4, 2026 · Lancet (London, England)
The public health challenges of children's and adolescents' digital media use: applying the digital determinants of health as an interpretive framework
More in Nuclear Medicine
View all →Sep 23, 2026 · The New England journal of medicine
Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome
Sep 23, 2026 · The New England journal of medicine
Clinical Uses of Common Genetic Variants Associated with Common Diseases
Sep 23, 2026 · The New England journal of medicine
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma
Sep 23, 2026 · The New England journal of medicine
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Sep 18, 2026 · Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
CMR and FDG PET/CT Imaging Phenotypes and their Association with Outcomes in Patients with Known or Suspected Myocarditis
Sep 14, 2026 · The New England journal of medicine
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
